The global corticosteroids market, valued at USD 5.70 billion in 2023, is projected to grow steadily, reaching USD 5.96 billion in 2024 and expanding further to USD 8.53 billion by 2032. This represents a compound annual growth rate (CAGR) of 4.6% during the forecast period (2024–2032). The market is being propelled by the rising prevalence of chronic inflammatory and autoimmune disorders, increasing awareness of effective treatment options, and growing demand in both developed and emerging economies.
Market Overview
Corticosteroids are a class of steroid hormones widely used for their potent anti-inflammatory, immunosuppressive, and analgesic properties. They are commonly prescribed in conditions such as asthma, arthritis, inflammatory bowel disease, allergic reactions, eczema, lupus, psoriasis, and organ transplant rejection prevention. Available in multiple formulations, including oral tablets, injectable solutions, inhalers, creams, and topical ointments, corticosteroids form a vital segment of the global pharmaceutical industry.
In recent years, the demand for corticosteroids has surged due to their effectiveness in treating respiratory illnesses (including severe COVID-19 cases), as well as their established role in managing long-term chronic diseases. The availability of generic versions, expansion of biopharmaceutical research, and the growth of online pharmacies are further accelerating market adoption worldwide.
Key Market Growth Drivers
- Rising Incidence of Chronic Diseases
Conditions like asthma, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis are on the rise globally, fueling corticosteroid demand. According to the WHO, over 262 million people suffer from asthma, while COPD remains a leading cause of death worldwide. Corticosteroids are often the frontline treatment for these disorders. - Widespread Use in Immunology & Dermatology
Corticosteroids remain a cornerstone treatment in dermatology (eczema, psoriasis, dermatitis) and immunology (lupus, multiple sclerosis). The increasing number of patients with skin and immune-related conditions is contributing to steady market expansion. - Growth of Inhaled & Topical Corticosteroids
Technological improvements in drug delivery systems—such as inhalers for asthma/COPD and topical gels for skin conditions—have made corticosteroid therapy safer, more targeted, and more accessible, boosting adoption rates. - Advancements in Clinical Research
Pharmaceutical companies are investing in novel corticosteroid formulations that minimize side effects while maintaining efficacy. Modified-release corticosteroids and combination therapies (corticosteroids with bronchodilators) are gaining momentum. - Expansion of Healthcare Access in Emerging Markets
Rising healthcare expenditure, growing middle-class populations, and the expansion of health insurance coverage in Asia-Pacific, Latin America, and the Middle East are increasing the accessibility of corticosteroid treatments.
Market Challenges
While growth prospects remain strong, several challenges could hinder market expansion:
- Side Effects and Safety Concerns: Long-term corticosteroid use is associated with severe side effects such as osteoporosis, hypertension, diabetes, weight gain, and immunosuppression. These risks often restrict prolonged prescriptions.
- Patent Expirations & Generic Competition: Several leading corticosteroid brands have lost patent exclusivity, resulting in price erosion and intensified competition from low-cost generics.
- Strict Regulatory Frameworks: Corticosteroid products must comply with stringent safety and efficacy regulations. Delays in drug approvals and manufacturing compliance issues may slow down market growth.
- Preference for Biologics & Alternative Therapies: With the rise of biologics and targeted therapies for autoimmune conditions, corticosteroids face competition in certain segments, particularly in advanced healthcare markets.
Regional Analysis
North America
North America remains the largest market, accounting for a significant share in 2023. The United States leads the region, driven by a high prevalence of asthma, COPD, and autoimmune diseases, along with a robust pharmaceutical industry. Government initiatives for chronic disease management and strong insurance coverage further support growth.
Europe
Europe represents another strong market, led by Germany, the UK, France, and Italy. Stringent healthcare systems, widespread awareness of corticosteroid therapies, and the presence of leading pharmaceutical players are contributing to market strength. However, regulatory restrictions on long-term corticosteroid use may limit growth in some therapeutic areas.
Asia-Pacific
The Asia-Pacific region is projected to grow at the fastest pace during the forecast period. Rising cases of respiratory diseases in China, India, and Southeast Asia, along with growing healthcare infrastructure and generic drug availability, are major growth enablers. The expanding biopharma industry in China and India is also expected to strengthen supply chains.
Latin America
Latin America is experiencing moderate growth, supported by increasing asthma and allergy prevalence, particularly in Brazil and Mexico. Improvements in healthcare funding and wider adoption of generics are boosting demand.
Middle East & Africa (MEA)
MEA is an emerging market with rising investments in healthcare and pharmaceutical infrastructure. Countries like Saudi Arabia, South Africa, and the UAE are key contributors, though limited affordability in some regions poses a challenge.
Market Segmentation
By Product Type
- Glucocorticoids: The largest segment, widely used for treating inflammatory and autoimmune conditions.
- Mineralocorticoids: Used in specific cases like Addison’s disease, representing a smaller but stable segment.
By Route of Administration
- Oral: Common for systemic treatments (arthritis, lupus, asthma).
- Injectable: Used for severe inflammatory conditions requiring rapid action.
- Inhaled: Fast-growing segment due to rising cases of asthma and COPD.
- Topical: Widely used in dermatology for eczema, psoriasis, and allergies.
By Application
- Respiratory Diseases (asthma, COPD)
- Dermatology (eczema, psoriasis, dermatitis)
- Autoimmune Disorders (lupus, rheumatoid arthritis)
- Oncology (as adjunct therapy in cancer care)
- Allergies (acute and chronic allergic conditions)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies (fastest-growing due to digital adoption)
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
https://www.polarismarketresearch.com/industry-analysis/corticosteroids-market
Key Companies
Several leading pharmaceutical and biotechnology companies are actively shaping the global corticosteroids market:
- Pfizer Inc. – Offers a broad portfolio of corticosteroid therapies across multiple indications.
- GlaxoSmithKline plc (GSK) – Strong presence in inhaled corticosteroids for respiratory care.
- Novartis AG – Focused on combination therapies and biologics, alongside corticosteroid treatments.
- Sanofi – Supplies corticosteroid products with a strong presence in Europe and North America.
- AstraZeneca plc – A leader in inhaled corticosteroid therapies for asthma and COPD.
- F. Hoffmann-La Roche Ltd. – Provides corticosteroid therapies within oncology and immunology segments.
- Bayer AG – Focuses on dermatological and systemic corticosteroid products.
- Teva Pharmaceutical Industries Ltd. – Major player in generic corticosteroid manufacturing.
- Mylan (Viatris Inc.) – Supplies cost-effective corticosteroid generics worldwide.
- Cipla Ltd. & Sun Pharmaceutical Industries Ltd. – Leading Indian companies driving corticosteroid adoption in Asia-Pacific and global markets.
Conclusion
The global corticosteroids market is set for consistent growth, supported by the increasing prevalence of chronic diseases, technological advancements in drug delivery systems, and expanding accessibility in emerging economies. However, challenges such as side effects, regulatory hurdles, and competition from biologics remain critical issues for industry players.
Pharmaceutical companies are focusing on innovation, strategic partnerships, and expansion into high-growth markets to stay competitive. The adoption of personalized therapies, digital health platforms, and improved corticosteroid formulations will likely define the next phase of market evolution.
More Trending Latest Reports By Polaris Market Research:
Lactation Support Supplements Market: A Therapeutic Alternative for Enhancing Breast Milk Supply
Platelet Rich Plasma (PRP) Market
Biobased Polyvinyl Chloride Market
Titanium & Titanium Alloys Dental Implants Market
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)